FibroGen Inc. (NASDAQ:FGEN) was up 4% on Wednesday . The stock traded as high as $17.42 and last traded at $17.10, with a volume of 218,255 shares. The stock had previously closed at $16.44.

Several equities research analysts have weighed in on FGEN shares. Credit Suisse Group AG restated a “buy” rating and set a $38.00 price target on shares of FibroGen in a report on Tuesday, May 10th. Zacks Investment Research upgraded FibroGen from a “sell” rating to a “hold” rating in a report on Tuesday, May 10th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. FibroGen presently has an average rating of “Buy” and an average price target of $33.50.

The company’s 50-day moving average price is $17.30 and its 200-day moving average price is $19.71. The firm’s market cap is $1.08 billion.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.11. Analysts forecast that FibroGen Inc. will post ($1.02) earnings per share for the current year.

In related news, CEO Thomas B. Neff sold 27,000 shares of FibroGen stock in a transaction on Wednesday, April 20th. The stock was sold at an average price of $19.98, for a total value of $539,460.00. Following the transaction, the chief executive officer now owns 3,579,353 shares in the company, valued at $71,515,472.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider K Peony Yu sold 2,344 shares of FibroGen stock in a transaction on Friday, June 10th. The shares were sold at an average price of $17.96, for a total value of $42,098.24. Following the completion of the transaction, the insider now owns 210,257 shares in the company, valued at approximately $3,776,215.72. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. Lebenthal Lisanti Capital Growth LLC boosted its position in shares of FibroGen by 2.5% in the fourth quarter. Lebenthal Lisanti Capital Growth LLC now owns 35,668 shares of the biopharmaceutical company’s stock worth $1,087,000 after buying an additional 863 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of FibroGen by 8,621.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 35,756 shares of the biopharmaceutical company’s stock worth $1,090,000 after buying an additional 35,346 shares during the last quarter. Tocqueville Asset Management L.P. boosted its position in shares of FibroGen by 60.8% in the fourth quarter. Tocqueville Asset Management L.P. now owns 40,200 shares of the biopharmaceutical company’s stock worth $1,214,000 after buying an additional 15,200 shares during the last quarter. Rhumbline Advisers boosted its position in shares of FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 3,675 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its position in shares of FibroGen by 0.8% in the fourth quarter. Nationwide Fund Advisors now owns 51,597 shares of the biopharmaceutical company’s stock worth $1,572,000 after buying an additional 393 shares during the last quarter.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.